-+ 0.00%
-+ 0.00%
-+ 0.00%

Aquestive Therapeutics Receives FDA Letter Identifying Deficiencies That Preclude Labeling Discussions For Anaphylm (Dibutepinephrine) Sublingual Film

Benzinga·01/09/2026 12:02:58
Listen to the news
  • Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time 
  • Receives confirmation from FDA that Agency's review of Anaphylm NDA application is ongoing and no final FDA decision has been made
  • Progresses global regulatory expansion activities in Canada, Europe, and the United Kingdom for Anaphylm
  • Unaudited cash and cash equivalents of approximately $120 million as of December 31, 2025